Baillie Gifford & Co. Cuts Stock Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Baillie Gifford & Co. cut its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 29.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,819,095 shares of the biotechnology company's stock after selling 4,956,765 shares during the period. Baillie Gifford & Co. owned about 4.62% of Adaptimmune Therapeutics worth $6,367,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vontobel Holding Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics in the third quarter valued at approximately $33,000. GSA Capital Partners LLP purchased a new position in Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. FMR LLC raised its holdings in Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock worth $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after buying an additional 98,581 shares during the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ADAP. Guggenheim dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. HC Wainwright decreased their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research note on Thursday, November 14th. Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research report on Wednesday, November 27th. Finally, StockNews.com downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics presently has an average rating of "Buy" and an average price target of $2.79.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP traded down $0.02 during trading hours on Friday, reaching $0.56. 485,956 shares of the company's stock were exchanged, compared to its average volume of 974,849. Adaptimmune Therapeutics plc has a 1-year low of $0.53 and a 1-year high of $2.05. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $143.16 million, a price-to-earnings ratio of -2.54 and a beta of 2.42. The company has a 50-day moving average of $0.59 and a 200 day moving average of $0.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.